Related Experiment Video
Updated: Jun 2, 2026
10:31
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
Published on: April 8, 2016
IL-10 implications in psoriasis.
Ahmad A Al-Robaee1, Abdullateef A Al-Zolibani, Hani A Al-Shobili
1Department of Dermatology, College of Medicine, Qassim University, Saudi Arabia.
International Journal of Health Sciences
|April 9, 2011
Summary
Interleukin-10 (IL-10) shows therapeutic potential for psoriasis by reducing inflammation and relapses. Its expression levels may serve as a key immune marker for this chronic skin condition.
Area of Science:
- Immunology
- Dermatology
Background:
- Interleukin-10 (IL-10) is a cytokine that regulates immune responses and terminates inflammation.
- Low IL-10 expression is observed in psoriasis, suggesting its involvement in the disease's pathophysiology.
- Conventional psoriasis therapies can induce IL-10 expression.
Purpose of the Study:
- To investigate the role and therapeutic potential of IL-10 in psoriasis.
- To evaluate IL-10's effects on immune cells and its clinical efficacy in psoriatic patients.
Main Methods:
- Clinical trials involving patients with established psoriasis and those in remission.
- Assessment of IL-10's effects on various immune cell populations, including antigen-presenting cells and T-cells.
- Monitoring of therapeutic effects, relapse rates, and disease-free intervals.
Main Results:
- IL-10 demonstrated moderate antipsoriatic effects and good tolerability in clinical trials.
- Long-term IL-10 application in patients in remission decreased relapse incidence and prolonged disease-free intervals.
- IL-10's therapeutic activity is attributed to modulating immune cell populations, not direct effects on keratinocytes.
Conclusions:
- IL-10 possesses significant clinical and therapeutic implications for psoriasis management.
- IL-10 genetic polymorphism and expression may function as a crucial immune marker in psoriasis.
- Further rigorous clinical trials are necessary to establish IL-10 as a standard antipsoriatic therapy.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...